NovaScan Fully Subscribes and Completes $3MM Financing
NovaScan, an emerging oncology company based in Chicago and Milwaukee, has announced that it has completed a $3MM financing. The convertible note financing was originally targeted for $2MM, but demand exceeded that amount and the company opportunistically added...
NovaScan Study on Cancer Recurrence and the Cole Frequency Published in a Peer-Reviewed Journal
NovaScan, a clinical stage oncology company based in Chicago and Milwaukee, recently had its publication titled Cole Relaxation Frequency as a Prognostic Parameter for Breast Cancer accepted in a peer-reviewed journal, the Journal of Patient Centered Research and...
NovaScan is Awarded Two More Patents, Further Protecting Company Innovations
NovaScan, a clinical stage oncology company based in Chicago and Milwaukee, was recently awarded patents for electrical scanning across tissue and for leverage of Cole frequency measurements to predict the likelihood of cancer recurrence. Patent No. 10,758,151 is a...
NovaScan welcomes Dr Charles Link to lead efforts in targeted drug delivery and to the NovaScan Board of Directors
NovaScan, an emerging clinical stage oncology company, is pleased to announce that Charles ‘Chuck’ Link MD, FACS has joined the Board of Directors of NovaScan. Dr Link is also a member of the NovaScan Executive Committee. Additionally, Chuck will lead NovaScan’s...
NovaScan Wins First Prize and Third Place in two International Competitions
November 15, 2019 NovaScan, an oncology company based in Chicago and Milwaukee, was awarded first prize in the BioPharma category in the InnoStars competition and third prize in the Innovate Hubei International Tech and Innovation Competition (InnoHubei), both in...
NovaScan Presented at American Society of Breast Surgeons Annual Meeting
NovaScan recently presented in a poster session at the 2018 Annual Meeting of the American Society of Breast Surgeons, where the company presented the results of a retrospective study that demonstrated that an elevated Cole frequency — which can be detected at the...
NovaScan Clincal Results Published in top Dermatology Journal
NovaScan’s clinical results in Mohs surgery were published in the highly regarded Journal of the American Academy of Dermatology. The article, titled "Bioimpedance Measurement as an Assessment of Margin Positivity in Mohs Surgical Specimens of Non-Melanoma Skin...
NovaScan in the Press
NovaScan was recently featured in the Milwaukee Journal Sentinel, describing our recent progress in commercializing our MarginScan device for use in Mohs procedures for skin cancer.